title: Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients.
authors.forename: J-C
authors.initials: JC
authors.lastname: Ianotto
authors.forename: A
authors.initials: A
authors.lastname: Tempescul
authors.forename: X
authors.initials: X
authors.lastname: Yan
authors.forename: P
authors.initials: P
authors.lastname: Delepine
authors.forename: R
authors.initials: R
authors.lastname: Le Calloch
authors.forename: E
authors.initials: E
authors.lastname: Hardy
authors.forename: J-R
authors.initials: JR
authors.lastname: Eveillard
authors.forename: N
authors.initials: N
authors.lastname: Mugnier
authors.forename: C
authors.initials: C
authors.lastname: Berthou
authors.forename: G
authors.initials: G
authors.lastname: Guillerm
mesh_terms: D059451:Biosimilar Pharmaceuticals / Q000008:administration & dosage*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D008223:Lymphoma / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D012189:Retrospective Studies
chemical_list: D059451:Biosimilar Pharmaceuticals; D016179:Granulocyte Colony-Stimulating Factor